Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany flag Germany · Delayed Price · Currency is EUR
452.70
-7.90 (-1.72%)
Mar 31, 2025, 2:20 PM CET

Vertex Pharmaceuticals Company Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.

Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.

Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated
Country United States
Founded 1989
Industry Biotechnology
Sector Healthcare
Employees 6,100
CEO Reshma Kewalramani

Contact Details

Address:
50 Northern Avenue
Boston, Massachusetts 02210
United States
Phone 617 341 6100
Website vrtx.com

Stock Details

Ticker Symbol VX1
Exchange Deutsche Börse Xetra
Fiscal Year January - December
Reporting Currency USD
ISIN Number US92532F1003
SIC Code 2836

Key Executives

Name Position
Reshma Kewalramani Chief Executive Officer
Charles Wagner Chief Financial Officer
Stuart Arbuckle Chief Operating Officer
Susie Lisa Head of Investor Relations